Tortoise Investment Management, LLC Relmada Therapeutics, Inc. Transaction History

Tortoise Investment Management, LLC

$905 Million
Q3 2024

A detailed history of Tortoise Investment Management, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Tortoise Investment Management, LLC holds 21,676 shares of RLMD stock, worth $7,803. This represents 0.01% of its overall portfolio holdings.

Number of Shares

21,676

Previous 21,676 -0.0%

Holding current value

$7,803

Previous $65,000 7.69%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$2.48 - $3.79 $6,200 - $9,475	2,500 Added 13.04%	21,676 $65,000
Q2 2023 Aug 07, 2023	BUY	$2.22 - $3.54 $14,685 - $23,417	6,615 Added 52.66%	19,176 $47,000
Q1 2023 May 09, 2023	BUY	$2.24 - $4.76 $11,146 - $23,685	4,976 Added 65.6%	12,561 $28,000
Q4 2022 Feb 03, 2023	BUY	$2.17 - $35.84 $4,991 - $82,432	2,300 Added 43.52%	7,585 $26,000
Q3 2022 Nov 04, 2022	SELL	$18.3 - $37.02 $14,566 - $29,467	-796 Reduced 13.09%	5,285 $196,000
Q1 2022 May 06, 2022	SELL	$16.72 - $26.99 $10,032 - $16,193	-600 Reduced 8.98%	6,081 $164,000
Q4 2021 Feb 10, 2022	BUY	$16.93 - $26.82 $19,469 - $30,843	1,150 Added 20.79%	6,681 $151,000
Q3 2021 Nov 04, 2021	BUY	$21.86 - $34.77 $26,144 - $41,584	1,196 Added 27.59%	5,531 $145,000
Q4 2020 Feb 05, 2021	BUY	$29.88 - $39.8 $14,940 - $19,900	500 Added 13.04%	4,335 $139,000
Q1 2020 May 05, 2020	BUY	$23.78 - $50.12 $22,234 - $46,862	935 Added 32.24%	3,835 $131,000
Q4 2019 Feb 06, 2020	BUY	$10.1 - $47.18 $29,290 - $136,822	2,900 New	2,900 $113,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.3M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tortoise Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tortoise Investment Management, LLC with notifications on news.

Account

Tortoise Investment Management, LLC Relmada Therapeutics, Inc. Transaction History